Objective: Depression after stroke and myocardial infarction (MI) is common but often assumed to be undertreated without reliable evidence being available. Thus, we aimed to determine treatment rates and investigate the application of guidelines in these conditions. Methods: Databases MEDLINE, EMBASE, PsycInfo, Web of Science, CINAHL, and Scopus were systematically searched without language restriction from inception to June 30, 2017. Prospective observational studies with consecutive recruitment reporting any antidepressant treatment in adults with depression after stroke or MI were included. Random-effects models were used to calculate pooled estimates of treatment rates. Results: Fifty-five studies reported 32 stroke cohorts (n = 8938; pooled frequency of depression = 34%, 95% confidence interval [CI] = 29%-38%) and 17 MI cohorts (n = 10,767; pooled frequency of depression = 24%, 95% CI = 20%-28%). In 29 stroke cohorts, 24% (95% CI = 20%-27%) of 2280 depressed people used antidepressant medication. In 15 MI cohorts, 14% (95% CI = 8%-19%) of 2381 depressed people used antidepressant medication indicating a lower treatment rate than in stroke. Two studies reported use of psychosocial interventions, indicating that less than 10% of participants were treated. Conclusions: Despite the high frequency of depression after stroke and MI and the existence of efficacious treatment strategies, people often remain untreated. Innovative strategies are needed to increase the use of effective antidepressive interventions in patients with cardiovascular disease.
INTRODUCTION S
troke and myocardial infarction (MI) are among the most common causes of disability worldwide, and their burden is likely to increase (1, 2) . Both diseases share a sudden onset, a threat to life (3), a need for long-term rehabilitation (4, 5) , and similar lifestyle risk factors (6) . In addition, depression affects 31% of all people at any time up to 5 years after stroke (7) and 28% of all people within 2 years of MI (8) . These conditions, referred to as post-stroke depression (PSD) and post-myocardial infarction depression (PMID), have an adverse impact on rehabilitation, including impaired functional outcome, reduced quality of life, lower medication adherence, increased risk of recurrent events, and higher mortality (8) (9) (10) . The efficacy of antidepressant drugs (ADTs), but not talking therapies, has been shown to be effective for the treatment of PSD, albeit with an associated increase in adverse events (11) . People with PMID have been shown to benefit from ADTs and psychosocial interventions, including relaxation therapy (12, 13) . Furthermore, ADTs are recommended in moderate to severe PSD and PMID, whereas those with milder symptoms should be closely monitored (14, 15) . Individual studies have also evaluated electroconvulsive therapy (11, 16) , herbal medicine (14) , and noninvasive brain stimulation (17) , but their efficacy has not been comprehensively demonstrated.
Proof of efficacy enhances the public's beliefs about an intervention and thereby leads to better implementation (18) . Nevertheless, use of ADTs is not a reliable indicator of adequate management of PSD. ADTs were found to reduce dependency, disability, neurological impairment, and pain after stroke, which may be attributable to beneficial effects on drive and motivation as well as on central nervous functioning (19, 20) . After MI, ADTs could not be shown to improve cardiac prognosis (21) (22) (23) , which may be due to low power for detecting mortality reduction in these trials (24) . However, based on the current evidence people with depression after stroke may have some indications for the prescription of ADTs, which do not apply to MI.
Despite the high frequency of PSD and PMID and the existence of efficacious treatment strategies, it is commonly stated that these patient groups are undertreated (25) (26) (27) (28) (29) (30) . However, studies rarely focus on the documentation of treatment rates resulting in a lack of comprehensive evidence. Therefore, we conducted a systematic review of the frequency of antidepressant treatment in people with PSD and PMID to determine the extent of undertreatment and to examine whether evidence-based recommendations are followed.
METHODS
This systematic review was undertaken according to the Meta-analyses Of Observational Studies in Epidemiology guidelines (31) and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (32) . The protocol was prospectively registered in the international prospective register of systematic reviews (CRD42016051232).
Study Selection
We included prospective observational studies with consecutive recruitment reporting data on treatment use at any given time point after stroke or MI. Randomized controlled trials, case-control studies, and crosssectional studies were excluded. Cohorts were included if participants (1) were 18 years or older, (2) had a clinical diagnosis of stroke or MI, and (3) were assessed for depressive symptoms using defined scores on standard screening instruments or depressive disorders (minor depression, dysthymia, major depression) applying ICD or DSM criteria. Finally, studies were included if they (4) reported the frequency of use of ADTs, psychosocial interventions, herbal medicine, electroconvulsive therapy, or noninvasive brain stimulation for the treatment of depression. Psychosocial interventions were defined as any treatment including telemedical or direct patient-professional interaction ranging from counseling to psychotherapy. Interventions with the sole purpose of education, information or social transfer, and occupational therapy were excluded.
Data Sources and Extraction
The literature search was conducted on MEDLINE, EMBASE, PsycInfo, Web of Science, CINAHL, and Scopus from inception to June 30, 2017. Databases were searched using MeSH terms and related keywords for stroke OR myocardial infarction AND depression AND prospective study design. The search strategy for MEDLINE is accessible at http://www.crd.york. ac.uk/PROSPEROFILES/51232_STRATEGY_20161010.pdf and was adjusted for other databases. After searching and excluding irrelevant studies via title and abstract, eligibility was examined using full-text articles. Reference lists of included articles and related review articles were manually searched. In an attempt to access all published studies worldwide, 17 non-English articles were reviewed in full text and translated from Chinese, Czech, Danish, French, German, Portuguese, Russian, and Spanish.
Study quality was assessed by grouping studies into three categories representing completeness of case selection (7) . The first group of population-based studies, considered the highest (least biased) quality, consisted of studies that attempted to recruit all people with stroke or MI, including those not admitted to hospital for acute care. The other two categories were hospital-based studies, which included all inpatients recruited from acute care medical wards in general hospitals, and rehabilitation-based studies, which included patients from rehabilitation wards or stroke/cardiac care units. Treatment rates were also pooled and compared among the World Health Organization (WHO) world regions (33) and between Organization for Economic Co-operation and Development (OECD)-member and nonmember countries, if applicable. Furthermore, treatment rates were pooled and compared among decades of publication (before 2000, 2000-2009, since 2010).
Study reports with evidence of overlapping recruitment sites, study dates, grant funding numbers, and similar or identical reported patient characteristics were considered to be from the same cohort. If several articles reported data from the same cohort, data were taken from the first publication of a given time point. If multiple instruments were used to assess depressive symptoms and their treatment at the same time point, data showing the highest proportion treated were included.
All authors were contacted for missing or additional data and to confirm suspected overlapping cohorts. Additional data were included if received before September 30, 2017.
Data Synthesis
Extracted data were stratified according to case selection and time of assessment after stroke or MI. Data assessed up to 3 months after the ictus were categorized as short term, from 3 up to 12 months as medium term, and 12 months or later as long term. Depression was categorized as mild (minor, mild depression, dysthymia) or moderate/severe (moderate, severe, major depression) according to the categories applied by study authors.
Frequencies of depressive symptoms and treatment use at the first assessment were pooled using the random-effects model of DerSimonian and Laird (34) . Sensitivity analyses included the comparison with fixedeffect models, treatment use at the last assessment, cohort size: small (n < 100) and large (n > 100), and interviewer-administered versus selfcompleted questionnaires to screen for depression. Publication bias was assessed by inspecting funnel plots and conducting Egger's regression (35) . Subgroup meta-analyses included patient groups with mild, moderate/severe, and no depression receiving treatment.
RESULTS
The applied search strategies identified more than 46,000 articles, of which 625 were reviewed in full text. Thirty-two stroke and 17 MI studies (in 55 articles) were included. Authors of 20 studies provided additional unpublished data (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) . The review process is illustrated in Figure 1 .
Description of the Study Samples
The 32 stroke cohorts included 8938 people, whereas the 17 MI cohorts consisted of 10,767 people. Six stroke and no MI studies were classified as population-based, 10 stroke studies and 6 MI studies were hospital-based, and 16 stroke and 11 MI studies were rehabilitation-based. According to the WHO categories (33), 21 stroke cohorts were from the European (36,37,39-42,54-69), 5 from the Western Pacific (38, (70) (71) (72) (73) , 1 from the Southeast Asian (74), 1 from the Eastern Mediterranean (43) , and 4 from the Americas region (57, (75) (76) (77) . Four stroke cohorts originated from non-OECD-member countries (71) (72) (73) (74) . Ten of the stroke articles were published before 2000 (41, 56, 58, 59, 61, 65, 68, 71, 76, 77) , 11 between 2000 and 2009 (36, 38, 40, 42, 55, 62, 67, 69, 70, 72, 74) , and 11 since 2010 (37, 39, 43, 54, 57, 60, 63, 64, 66, 73, 75) . Eleven MI cohorts were from the Americas (United States and Canada) (44) (45) (46) (47) (48) 51, (78) (79) (80) (81) (82) , whereas six cohorts were from the European region (49, 50, 52, 53, 83, 84) . All MI cohorts were collected in member countries of the OECD (Table 1) People with stroke were assessed between 2 weeks and 5 years after the ictus. The minimum age criterion of 18 years or older could not be confirmed in seven studies (56, 66, 67, 71, (74) (75) (76) . One study (59) included people 15 years or older and was included because of an assumed small number of people younger than 18 years and a large sample size. Further study details are listed in Table 1 . The pooled frequency of PSD in 32 cohorts was 34% (95% confidence interval [CI] = 29%-38%) with significant heterogeneity among studies (p < .001) and a significant intercept in Egger's regression (p < .001), indicating that smaller studies reported higher frequencies.
People with MI were assessed between 1 day and 18 months after the ictus. The age criterion could not be confirmed in three studies (79, 82, 84) . Further study details are listed in Table 2 . The pooled frequency of PMID in 17 cohorts was 24% (95% CI = 20%-28%) with significant heterogeneity (p < .001) and a nonsignificant intercept in Egger's regression (p = .19).
Treatment of PSD
No treatment other than ADTs or psychosocial interventions were reported. One stroke study reported use of psychotherapy (none of the 89 people with PSD received psychotherapy) (60) , and another reported if people were referred to a psychiatric service in addition to receiving ADTs (none of 11 people with PSD were referred) (41) . The studies did not specify these treatments further. Hence, 31 studies reported use of ADTs. One of these did not report the cut-off used for depression assessment and was excluded from analyses (55) . Visual investigation of the funnel plot led to exclusion of a further study representing an outlier with small sample (62) . Results of sensitivity analyses were identical if this study was included or excluded.
Finally, 29 cohorts consisting of 8634 people with stroke were included in random-effects analyses of ADT use. Frequency of PSD in these cohorts (32%, 95% CI = 27%-37%) was not significantly different from the frequency in all 32 cohorts. The pooled estimate of ADT use was 24% (95% CI = 20%-27%) in 2280 people with PSD with significant heterogeneity among studies (p < .001) and a nonsignificant intercept in Egger's regression (p = .082). Sensitivity analyses did not produce any significantly different result. The forest plot (Figure 2 ) illustrates the pooled estimates for different time windows and recruitment types. There was no significant difference in treatment rates among population-based (21%, 95% CI = 14%-28%), hospitalbased (21%, 95% CI = 15%-27%), and rehabilitation-based studies (28%, 95% CI = 22%-34%). Analyses comparing pooled treatment rates between cohorts from different WHO world regions (33) , between OECD member and nonmember countries as well as among decades of publication produced no significantly different results.
Data on ADT use could be extracted from three cohorts with mild depression (41, 42, 71) and six cohorts with moderate to severe depression (37, 39, 41, 42, 67, 71) . ADTs were significantly less often used in PSD with mild depression (9%, 95% CI = 7%-12%) than in PSD with moderate to severe depression (22%, 95% CI = 14%-29%). Heterogeneity of studies was not significant in either group (p > .30). Furthermore, 12 studies reported ADT use in non-depressed people with stroke (39) (40) (41) 54, 57, 58, 64, (69) (70) (71) 75, 77) . The pooled estimate of these frequencies was 11% (95% CI = 7%-14%) with significant heterogeneity among studies (p < .001) and a nonsignificant intercept in Egger's regression (p > .90). In addition, one study reported that 18% of those not depressed and treated at 12 months were previously depressed at 3 months (57) and one study reported that 64% who were not depressed and treated at 6 months were previously depressed at 7 weeks (54).
Treatment of PMID
No treatment other than ADTs or psychosocial interventions were reported. One study reported the use of psychopharmacology and/or psychotherapy by 3 of 5 with PMID (60.0%) (78), one study reported use of psychiatric treatment by 3 of 18 with PMID (16.6%) (82) , and one study reported use of psychosocial interventions for depression by 72 of 759 with PMID (9.5%) (81) without further description of these interventions.
The 15 studies reporting use of ADTs consisted of 10,635 with MI who were included in the random-effects analyses. The pooled frequency of PMID in these cohorts (25%, 95% CI = 21%-30%) was not significantly different from the frequency in all 17 cohorts. The pooled frequency of ADT use was 14% (95% CI = 8%-19%) in 2381 with PMID and hence significantly lower than in PSD. Heterogeneity among studies was significant (p < .001) with a nonsignificant intercept in Egger's regression (p = .062). The estimate did not change in sensitivity analyses. Furthermore, people in hospital-based studies received ADTs more often (19%, 95% CI = 15%-24%) than people in rehabilitation-based studies (8%, 95% CI = 4%-13%). The 10 short-term studies showed a pooled frequency of 16% (95% CI = 11%-21%) (44, 45, (48) (49) (50) (51) (52) (53) 80, 81) , the three medium-term studies a frequency of 12% (95% CI = 0%-25%) (46, 83, 84) , and the two long-term studies a frequency of 6% (95% CI = 1%-10%) (47, 79) , demonstrating a significant difference between frequencies in the short-term rehabilitation-based study and the two long-term rehabilitation-based studies. Comparing pooled treatment rates between cohorts from the European region and the region of the Americas as well as among decades of publication yielded no significant difference.
DISCUSSION
This meta-analysis provides the first comprehensive evidence of depression treatment rates after stroke and MI. Although more PSD cohorts could be identified, PMID cohorts were usually larger resulting in similar numbers of people being included. The frequencies of depressive symptoms were in the same range as in other systematic reviews on PSD (7) and PMID (8) , supporting the generalizability of our findings. Only a few study authors reported the use of treatments other than ADTs (41, 60, 78, 81, 82) . This may be explained by the lack of evidence of other efficacious treatments for people with PSD (11), whereas pharmacological and psychosocial interventions have proven efficacious for PMID (12) . This may also be due to the investigation of more innovative interventions in PMID such as the telephone-based collaborative care program of the MOSAIC trial (85) . Because only few or no people used psychosocial interventions in the studies reporting these treatments and use of psychosocial interventions may be documented less often in outpatient settings, this finding may also be attributed to reporting and measurement biases. Every fourth person with PSD and every seventh person with PMID reported using ADTs indicating that only a small proportion of people with depression after stroke and MI receive evidencebased treatment. Clinical trials have proven the efficacy of ADTs in both disorders (11, 12) , but they are only effective if they are prescribed and taken (18) . In addition, some studies indicate higher mortality in people with untreated PSD and PMID (81, 86) . However, the ENRICHD trial did not show a reduction of late mortality in people with PMID who were treated with cognitive behavioral therapy and sertraline but demonstrated increased late mortality in people whose depression is refractory to treatment (22) . Possible reasons for undertreatment include insufficient assessment and follow-up of psychological status (47, 87) as well as uncertainty due to comorbidities and polypharmacy, which is common in people with stroke and MI (25) . Furthermore, depression may be perceived as a natural reaction to stroke or MI, which therefore is assumed to require no further treatment (88) . Depressive symptoms such as lack of energy, hopelessness, and withdrawal may also contribute to people stopping rehabilitation, follow-up visits, and medications (46) . In addition, patients may want to avoid the label and associated stigma of mental illness and therefore withdraw from treatment (89) . Frequency of treatment was not different based on case selection in PSD, indicating similar health care practices across all settings. Treatment rates in rehabilitation-based PMID cohorts were significantly lower than in hospital-based cohorts, which contrasts especially with stroke cohorts showing the descriptively highest frequency of treatment in rehabilitation settings. The difference between MI cohorts may be attributable to better access of people with MI to mental health professionals in hospital compared with rehabilitation due to counsel service. Although guidelines list psychological evaluation as an essential part of cardiac rehabilitation (84) , evidence suggests low psychological expertise in this setting (85) . Whereas cardiac rehabilitation usually focuses on the prevention of recurrent events using pharmacological and lifestyle interventions (84) , stroke rehabilitation includes neuropsychological assessment and treatment of cognitive impairment (86) . Therefore, mental health expertise may be higher in hospital and stroke rehabilitation compared with cardiac rehabilitation possibly resulting in better recognition and treatment of depressive symptoms. Treatment rates in PSD and PMID did not differ between world regions (33) or by OECD membership where most cohorts were from Europe, North America, and/or OECD countries. In addition, treatment rates did not differ depending on year of publication despite major developments in the health care of people with stroke and MI for the last decades. Three studies (37, 40, 69) distinguishing classes of ADTs reported SSRIs being most frequently used in PSD, which is in line with research favoring SSRIs as a pharmacological treatment (19) .
PSD was more frequently treated than PMID and a tenth of nondepressed people received ADTs after stroke. This may be based on the clinical consideration of findings supporting the efficacy of ADTs for physical and functional rehabilitation after stroke (19, 20) . In addition, people with more severe PSD received ADTs more frequently, which is in keeping with evidence-based guideline recommendations (15) , better recognition (90), and higher need (91) .
Although our findings are limited by the high variability of the assessment tools used, criteria for depressive symptoms, assessment times, methods for collecting data on treatment use, and the selection criteria within the cohorts, they remain consistent in sensitivity analyses. As a further strength of this meta-analysis, we included many unpublished data sets, which were provided by original authors. However, it must be noted that the reported use of antidepressants may not indicate adequate treatment of depression because they may also be described to improve physical and functional rehabilitation or treat anxiety (19, 20) . Furthermore, this meta-analysis excluded interventions solely providing information or education because they were not investigated in randomized controlled trials up to now. Nevertheless, people with PSD or PMID may benefit from these interventions. Finally, many cohorts had to be excluded because they assessed depressive symptoms in SYSTEMATIC REVIEW/META-ANALYSIS
